The purpose of this study was to evaluate if there was a difference in serum markers of CKD-MBD (calcium, phosphorus, PTH) or medication burden post implementation of a pharmacist–dietitian-led, patient-centered approach to managing CKD-MBD in hemodialysis patients compared with the program’s previous standard of practice. The gene discussed is PTH; the disease is chronic kidney disease.